Aussies Chalmers, Titmus, Larkin & the Campbells Headline Swim Stars in ISL
10.9.2019 16:19:00 EEST | Business Wire | Press release
Australian stars Kyle Chalmers, Cate and Bronte Campbell, Ariarne Titmus and Mitch Larkin will compete in a new professional league pitting the world’s best swimmers against each other in a revolutionary club-based competition, which will be shown exclusively live in Australia on 7plus.
The International Swimming League (ISL) will hold its inaugural meet in Indianapolis next month, when eight teams – four from the United States and four from Europe – will compete over two days in a full program of events over 50m to 400m.
This will be the first of seven ISL meets across the United States and Europe in 2019, with the top four teams qualifying for the final in Las Vegas in December.
With more than $5 million in prize money at stake, and most of swimming’s current Olympic champions and world-record holders set to take part, the competition will be fierce and is bound to showcase many of the captivating rivalries expected to take centre stage at the Olympic Games Tokyo 2020.
The international big names competing include Titmus’ great rival Katie Ledecky and fellow giants of the pool Adam Peaty, Sarah Sjostrom, Ryan Murphy, Federica Pellegrini, Chad le Clos and Nathan Adrian.
The Aussie contingent taking part also includes Emma McKeon, Cam McEvoy, Emily Seebohm, Clyde Lewis, Jess Hansen and Holly Barratt, giving swimming fans a chance like never before to track the progress of our brightest Olympic Games medal hopes as Tokyo 2020 draws ever closer.
Seven’s Head of Sport Saul Shtein said: “The ISL will give swimming an established place in the annual sporting calendar and offers sports fans the chance to watch the world’s best compete regularly in an exciting new format, while this inaugural season should also provide a tantalising lead-in to Tokyo 2020. We’re thrilled to bring it to our viewers and to be adding more premium live content to 7plus.”
Kontantin Grigorishin, ISL President, declared: "We are very excited about this partnership with Seven Sport, which will allow millions of fans in Australia to experience full live coverage of International Swimming League. The heart of swimming beats in Australia and will beat even stronger from October 6 with the first ever match of ISL in Indianapolis."
Swimming fans will also be able to watch highlights of every ISL meet on 7TWO and 7plus.
In 2020, Seven is the home of the Australian swimming Olympic Games trials and Tokyo 2020.
TV Broadcast times: October 6-7 ISL – Group A: Match 1 Indianapolis, USA Sydney 5.00am LIVE on 7plus Melbourne 5.00am LIVE on 7plus Brisbane 5.00am LIVE on 7plus Adelaide 4.30am LIVE on 7plus Perth 3.00am LIVE on 7plus
October 13-14 ISL – Group A: Match 2 Naples, Italy Sydney 4.00am LIVE on 7plus Melbourne 4.00am LIVE on 7plus Brisbane 3.00am LIVE on 7plus Adelaide 3.30am LIVE on 7plus Perth 1.00am LIVE on 7plus
October 20-21 ISL – Group B: Match 1 Dallas, USA Sydney 6.00am LIVE on 7plus Melbourne 6.00am LIVE on 7plus Brisbane 5.00am LIVE on 7plus Adelaide 5.30am LIVE on 7plus Perth 3.00am LIVE on 7plus
October 27-28 ISL – Group B: Match 2 Budapest, Hungary Sydney 4.00am LIVE on 7plus Melbourne 4.00am LIVE on 7plus Brisbane 3.00am LIVE on 7plus Adelaide 3.30am LIVE on 7plus Perth 1.00am LIVE on 7plus
November 17-18 ISL – USA Derby Washington DC, USA Sydney 6.00am LIVE on 7plus Melbourne 6.00am LIVE on 7plus Brisbane 5.00am LIVE on 7plus Adelaide 5.30am LIVE on 7plus Perth 3.00am LIVE on 7plus
November 24-25 ISL – Europe Derby London, UK Sydney 4.00am LIVE on 7plus Melbourne 4.00am LIVE on 7plus Brisbane 3.00am LIVE on 7plus Adelaide 3.30am LIVE on 7plus Perth 1.00am LIVE on 7plus
December 21-22 ISL – Final Las Vegas, USA TBC
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005683/en/
Contact information
Nick Bowen
0438 777 459.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom